Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

MacroGenics Inc. (MGNX)

10.33   0.64 (6.6%) 12-12 16:00
Open: 9.58 Pre. Close: 9.69
High: 10.39 Low: 9.38
Volume: 676,020 Market Cap: 505M
Macrogenics Inc is a clinical-stage biopharmaceutical company. It focusses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.403 - 10.441 10.441 - 10.472
Low: 9.284 - 9.329 9.329 - 9.365
Close: 10.257 - 10.332 10.332 - 10.393

Technical analysis

as of: 2019-12-12 4:32:46 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 12.32     One year: 14.39
Support: Support1: 8.62    Support2: 7.43
Resistance: Resistance1: 10.55    Resistance2: 12.32
Pivot: 9.41
Moving Average: MA(5): 9.77     MA(20): 9.19
MA(100): 11.74     MA(250): 14.76
MACD: MACD(12,26): 0.12     Signal(9): -0.04
Stochastic oscillator: %K(14,3): 80.20     %D(3): 83.44
RSI: RSI(14): 62.42
52-week: High: 32.32  Low: 7.43  Change(%): -24.5
Average Vol(K): 3-Month: 54579  10-Days: 65718

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
MGNX has closed above the upper band by 6.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 28% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2019-11-22
The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) (raised full-year guidance following completion of Otezla purchase from Celgene) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cue Biopharma Inc (NASDAQ: CUE ) Epizyme Inc (NASDAQ: EPZM ) Kamada Ltd. (NASDAQ: KMDA ) Kodiak Sciences Inc (NASDAQ: KOD ) Molecular Templates Inc (NASDAQ: MTEM ) Recro Pharma Inc (NASDAQ: REPH ) (completed spin-off of Baudax Bio in a bid to a become a pure play CDMO) Down In The Dumps (Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed NV (NASDAQ: AFMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) CareDx Inc (NASDAQ: CDNA ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Genprex Inc (NASDAQ: GNPX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Interpace Biosciences Inc (NASDAQ: IDXG ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its previously announced common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) MacroGenics Inc (NASDAQ: MGNX ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) Neon Therapeutics Inc (NASDAQ: NTGN ) (announced a changed focus and the elimination of 24% of workforce) Novavax, Inc. (NASDAQ: NVAX ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics …

2019-11-12
TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)---- $MGNX #MGNX--TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc.

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 48.92
Shares Float (M) 44.22
% Held by Insiders 7.12
% Held by Institutions 78.27
Shares Short (K) 4370
Shares Short P. Month (K)

Stock Financials

EPS -3.580
Book Value (p.s.) 5.220
PEG Ratio 0.01
Profit Margin
Operating Margin -328.91
Return on Assets (ttm) -31.9
Return on Equity (ttm) -61.8
Qtrly Rev. Growth -9.9
Gross Profit (p.s.) -2.672
Sales Per Share
EBITDA (p.s.) -3.456
Qtrly Earnings Growth
Operating Cash Flow (M) -123.45
Levered Free Cash Flow (M) -76.49

Stock Valuations

P/E -2.89
P/E Growth Ratio 0.07
P/BV 1.98
P/S 8.75
P/CF -4.09

Dividends & Splits

Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.